Total Payments
$10,730
2024 Payments
$9,025
Companies
14
Transactions
48
Medicare Patients
615
Medicare Billing
$114,233
Payment Breakdown by Category
Consulting$9,577 (89.3%)
Food & Beverage$1,021 (9.5%)
Research$109.20 (1.0%)
Education$22.76 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,577 | 3 | 89.3% |
| Food and Beverage | $1,021 | 43 | 9.5% |
| Unspecified | $109.20 | 1 | 1.0% |
| Education | $22.76 | 1 | 0.2% |
Payments by Type
General
$10,621
47 transactions
Research
$109.20
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. | $8,752 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $825.00 | 2 | $0 (2019) |
| ABBVIE INC. | $464.26 | 20 | $0 (2024) |
| GENZYME CORPORATION | $121.84 | 6 | $0 (2021) |
| Eli Lilly and Company | $109.20 | 1 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $86.09 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $85.34 | 4 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $79.47 | 4 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $58.70 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $43.75 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,025 | 8 | Verrica Pharmaceuticals Inc. ($8,752) |
| 2023 | $124.60 | 6 | AbbVie Inc. ($44.59) |
| 2022 | $292.18 | 16 | ABBVIE INC. ($179.99) |
| 2021 | $62.07 | 3 | AbbVie Inc. ($40.99) |
| 2020 | $109.20 | 1 | Eli Lilly and Company ($109.20) |
| 2019 | $272.69 | 3 | Merck Sharp & Dohme Corporation ($225.00) |
| 2018 | $680.42 | 6 | Merck Sharp & Dohme Corporation ($600.00) |
| 2017 | $163.71 | 5 | Janssen Scientific Affairs, LLC ($86.09) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Consulting Fee | Cash or cash equivalent | $8,752.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Dermatology | ||||||
| 07/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Immunology | ||||||
| 07/26/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $130.00 | General |
| 05/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Immunology | ||||||
| 04/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: Ophthalmology | ||||||
| 01/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $34.57 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $29.42 | General |
| Category: Immunology | ||||||
| 08/14/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Dermatology | ||||||
| 06/05/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.33 | General |
| Category: Immunology | ||||||
| 05/15/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Dermatology | ||||||
| 04/09/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: IMMUNOLOGY | ||||||
| 03/26/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: ANTIBIOTIC | ||||||
| 09/19/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.72 | General |
| Category: Immunology | ||||||
| 07/27/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: IMMUNOLOGY | ||||||
| 05/09/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: ANTIBIOTIC | ||||||
| 04/27/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: IMMUNOLOGY | ||||||
| 04/22/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: IMMUNOLOGY | ||||||
| 03/23/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: ANTIBIOTIC | ||||||
| 03/07/2022 | ABBVIE INC. | RINVOQ (Biological), RINVOQ | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: IMMUNOLOGY | ||||||
| 03/07/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: IMMUNOLOGY | ||||||
| 02/23/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $109.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 231 | 403 | $156,510 | $30,769 |
| 2022 | 3 | 107 | 253 | $154,015 | $27,008 |
| 2021 | 4 | 139 | 342 | $205,250 | $37,137 |
| 2020 | 4 | 138 | 273 | $126,808 | $19,319 |
Total Patients
615
Total Services
1,271
Medicare Billing
$114,233
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 142 | $73,610 | $14,511 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 71 | $51,255 | $9,685 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 38 | $14,400 | $2,863 | 19.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $6,775 | $1,753 | 25.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 18 | 18 | $8,100 | $1,537 | 19.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 31 | 42 | $1,647 | $352.80 | 21.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 75 | $723.73 | $66.14 | 9.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 143 | $88,165 | $14,506 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 67 | $46,550 | $9,150 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 43 | $19,300 | $3,352 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 211 | $127,020 | $22,773 | 17.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 30 | 76 | $50,820 | $10,131 | 19.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 41 | $18,450 | $3,215 | 17.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 11 | 14 | $8,960 | $1,018 | 11.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 196 | $94,370 | $14,803 | 15.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 33 | 45 | $19,380 | $2,793 | 14.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 11 | 11 | $6,455 | $890.65 | 13.8% |
| 11901 | Injection of more than 7 skin growths | Office | 2020 | 16 | 21 | $6,603 | $833.31 | 12.6% |
About Dr. Steven Cohen, M.D
Dr. Steven Cohen, M.D is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1235124355.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Cohen, M.D has received a total of $10,730 in payments from pharmaceutical and medical device companies, with $9,025 received in 2024. These payments were reported across 48 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($9,577).
As a Medicare-enrolled provider, Cohen has provided services to 615 Medicare beneficiaries, totaling 1,271 services with total Medicare billing of $114,233. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 09/14/2005
- Last Updated 10/01/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1235124355
Products in Payments
- YCANTH (Drug) $8,752
- MK-8931 (Drug) $825.00
- SKYRIZI (Biological) $181.08
- STELARA (Biological) $86.09
- TREMFYA (Drug) $85.34
- RINVOQ (Biological) $84.49
- NUZYRA (Drug) $79.47
- Humira (Biological) $68.69
- DUPIXENT (Drug) $67.00
- COSENTYX (Drug) $58.70
- Sotyktu (Drug) $43.75
- SPEVIGO (Drug) $34.57
- DERMATITIS - DISEASE (Drug) $33.76
- Izervay (Drug) $33.41
- Cimzia (Drug) $22.76
- LIBTAYO (Biological) $21.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M